Treating low blood sugar prevents brain damage in newborn babies: study
Stabilising low blood sugar levels in newborns with hypoglycemia, or low blood sugar, appears to prevent brain damage,
according to the first study of its kind.
Treating low blood sugar prevents brain damage in newborn babies: study
Stabilising blood sugar levels in newborns with hypoglycemia, or low blood sugar, appears to prevent brain damage,
according to the first study of its kind.
The study, led by the Liggins Institute at the University of Auckland in New Zealand, is published today in The New
England Journal of Medicine. It was funded by the National Institutes of Health (NIH) in the United States and the
Health Research Council (HRC) of New Zealand.
The lead researcher, Distinguished Professor Jane Harding, says the study shows that if doctors treat a baby with
hypoglycemia to keep the blood sugar above a safety threshold, there is no increase in the risk of brain damage. This
threshold, already widely used, is 2.6 millimoles per litre or 47 milligrams per decilitre.
The study has also found that babies with blood sugar levels that were higher than usual appeared to be at risk of brain
damage.
“Hypoglycemia is the single most preventable cause of brain damage in newborns. Up to 30
percent of newborns are at risk, 15 percent will be affected to at least some degree, and around 10 percent end up
admitted to intensive care,” says Professor Harding.
“We know that a baby with a blood glucose level that is too low for too long will suffer neurological damage, but there
has been debate about just how low, for how long, and in which babies. This is the first clear evidence that treating
babies to keep their blood sugar above a widely-used safety intervention threshold does indeed protect them.”
The Liggins Institute researchers - working with other colleagues at the University of Auckland and the University of
Waterloo - also found that babies who had blood glucose levels that rose too high or which fluctuated widely during the
first 48 hours of their lives were more likely to have brain damage.
“It may be that it’s not only important to keep blood glucose levels from dropping too low, but also to keep them from
swinging too high, too fast, but we need further studies to confirm that link,” says Professor Harding.
She says the study also shows that while there are clear benefits to the current clinical practice in many parts of the
world – which is to test at-risk infants regularly - the introduction of continuous monitoring is not necessary.
“When a glucose metre is used to monitor a baby continuously, it often picks up brief drops in glucose to below the safe
level. However, we have found no link between these brief falls and any increase in neurological damage.
“Glucose is the sugar on which the brain depends most for fuel. The main factors that put a baby at risk of low blood
glucose are being born of a diabetic mother, small or large at birth, or pre-term,” Professor Harding says.
When a mother has diabetes the fetus tries to compensate for her high blood glucose level by producing more insulin to
clear the excess glucose from its bloodstream. But this production of extra insulin continues once the baby is cut off
from the excess glucose supply at birth, and glucose levels soon tumble. In babies who are pre-term or small at birth,
the baby often cannot produce enough glucose because it lacks the fat and other body stores that are used to produce it.
The Children with Hypoglycemia and their Later Development study (CHYLD) examined 404 two-year-old children who were
born at risk of hypoglycemia at Waikato Hospital in Hamilton, New Zealand. Their blood sugar levels were raised with
extra food, buccal dextrose gel or intravenous dextrose if needed.
Researchers tested them at two years old for neurosensory impairment and processing difficulties – including
developmental progress, cognitive and language skills, vision, hearing, physical co-ordination and executive
functioning.
The National Institutes of Health, (one of the study’s funders), describes the findings as “extremely reassuring”.
“There is now firm evidence that physicians can provide an essential treatment to prevent brain damage without concern
that there might be any unforeseen increase in risk to the newborn,” says Tonse Raju, M.D., Chief of the Pregnancy and
Perinatology Research Branch at NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development.
The Health Research Council of New Zealand, another funder, welcomes what it calls “an exceptional piece of research”.
Chief Executive Professor Kath McPherson says it fills a major gap in knowledge about the effects of low blood sugar in
newborns on long-term development.
“We’re delighted to support this research, which already is leading to re-thinking the treatment of low and high blood
sugar in newborns in New Zealand and around the world. New Zealand punches far above its weight in research concerning
paediatrics and reproductive medicine and this is another example of that excellence,” says Professor McPherson.
ENDS